| 1 |
Gutterman DD. Silent myocardial ischemia[J]. Circ J, 2009, 73 (5): 785-797.
|
| 2 |
Shirani J, Dilsizian V. Screening asymptomatic patients with type 2 diabetes mellitus for coronary artery disease: does it improve patient outcome[J]. Curr Cardiol Rep, 2010, 12 (2): 140-146.
|
| 3 |
Maeda A, Ando H, Asai T, et al. Differential impacts of CYP2C19 genepolymorphisms on the antiplatelet effects of clopidogrel and ticlopidine[J]. Clin Pharmacol Ther, 2011, 89 (2): 229-233.
|
| 4 |
中华医学会心血管病学分会介入心脏病学组，中华心血管病杂志编辑委员会. 中国经皮冠状动脉介入治疗指南2012（简本）[J/CD]. 中华危重症医学杂志（电子版），2012，5(3):169-180.
|
| 5 |
郭明，杨杰，张亚梅，等. 急性心肌梗塞介入治疗患者早期应用β受体阻滞剂对心功能和自主神经功能状态的影响[J/CD]. 中华危重症医学杂志（电子版），2016，9(6):380-383.
|
| 6 |
Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling[J]. Diabetes Care, 2004, 27 (6): 1487-1495.
|
| 7 |
Geloneze B, Vasques AC, Stabe CF, et al. HOMA1-IR and HOMA2-IR indexes in identifying insulin resistance and metabolic syndrome: Brazilian metabolic syndrome study (BRAMS)[J]. Arq Bras Endocrinol Metabol, 2009, 53 (2): 281-287.
|
| 8 |
郭环宇，胡细连，曾文平，等. 老年冠心病患者PCI术后气虚血瘀证对抗栓疗效的影响及其与CYP2C19*2基因多态性的相关性[J]. 中国老年学杂志，2016，36(14):3417-3419.
|
| 9 |
Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events[J]. N Engl J Med, 2009, 360 (4): 363-375.
|
| 10 |
Blanchet Deverly A, Amara M, Larifla L, et al. Silent myocardial ischaemia and risk factors in a diabetic Afro-Caribbean population[J]. Diabetes Metab, 2011, 37(6): 533-539.
|
| 11 |
Smagulova G, Kulmurzaeva N, Seytmaganbetova N, et al. The first results of the prevalence of CYP2C19 genepolymorphism in patients with acute coronary syndrome in the Aktyubinsk population[J]. Georgian Med News, 2016 (253): 61-66.
|
| 12 |
Ingelman-Sundberg M, Sim SC, Gomez A, et al. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects[J]. Pharmacol Ther, 2007, 116 (3): 496-526.
|
| 13 |
Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects[J]. Blood, 2006, 108 (7): 2244-2247.
|
| 14 |
Giusti B, Gori AM, Marcucci R, et al. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients[J]. Pharmacogenet Genomics, 2007, 17 (12): 1057-1064.
|
| 15 |
Brandt JT, Close SL, Iturria SJ, et al. Common pol-ymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel[J]. J Thromb Haemost,2007, 5 (12): 2429-2436.
|
| 16 |
Chen M, Liu XJ, Yan SD, et al. Association between cytochrome P450 2C19 polymorphism and clinical outcomes in Chinese patients with coronary artery disease[J]. Atherosclerosis, 2012, 220 (1): 168-171.
|
| 17 |
Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel[J]. N Engl J Med, 2009, 360 (4): 354-362.
|
| 18 |
Trenk D, Hochholzer W, Fromm MF, et al. Cytoch-rome P450 2C19 681G > A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents[J]. J Am Coll Cardiol, 2008, 51 (20): 1925-1934.
|
| 19 |
Kim KA, Park PW, Hong SJ, et al. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance[J]. Clin Pharmacol Ther, 2008, 84 (2): 236-242.
|
| 20 |
Frere C, Cuisset T, Morange PE, et al. Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome[J]. Am J Cardiol, 2008, 101 (8): 1088-1093.
|
| 21 |
Oh IY, Park KW, Kang SH, et al. Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents[J]. Heart. 2012, 98 (2): 139-144.
|
| 22 |
Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program[J]. Diabetes Care, 1998, 21 (12): 2191-2192.
|
| 23 |
Geloneze B, Vasques AC, Stabe CF, et al. HOMA1-IR and HOMA2-IR indexes in identifying insulin resistance and metabolic syndrome: Brazilian Metabolic Syndrome Study (BRAMS)[J]. Arq Bras Endocrinol Metabol, 2009, 53 (2): 281-287.
|
| 24 |
李霖，李红，王舟，等. HOMA 2方法评价2型糖尿病患者胰岛素抵抗和胰岛β细胞功能[J]. 浙江预防医学，2008，20(8):1-2,5.
|
| 25 |
周薇霞，邢玉波，俞宁娟. 2型糖尿病患者血清视黄醇结合蛋白4含量与胰岛素抵抗的相关性分析[J/CD]. 中华危重症医学杂志（电子版），2014，7(1):56-58.
|
| 26 |
Pialti PM, Monti LD, Contl M, et al. Hypetriglycericlima and hyper-insulinemia are potent inducers of endothelin-J release in humans[J]. Diabetes, 1996, 45 (3): 316-321.
|
| 27 |
Byrkjeland R, Edvardsen E, Njerve IU, et al. Insulin levels and HOMA index are associated with exercise capacity in patients with type 2 diabetes and coronary artery disease[J]. Diabetol Metab Syndr, 2014, 6 (1): 36.
|